Related Experiment Video
Updated: Apr 19, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
7.5K
Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?
1IFI Institute at the Asklepios Klinik St Georg Hamburg, University of Hamburg, Hamburg, Germany.
Summary
Combination therapy for chronic hepatitis B, using pegylated interferon alpha (PEG-IFN) with nucleos(t)ide analogues (NAs), shows virological benefits but lacks evidence for long-term patient outcomes. Current guidelines do not recommend this approach due to missing pivotal studies.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis B treatment involves pegylated interferon alpha (PEG-IFN) and nucleos(t)ide analogues (NAs).
- NAs offer good tolerance and potent antiviral effects, while PEG-IFN provides a finite treatment course without resistance and potential for durable response.
- Combination therapy is explored due to differing mechanisms of action.
Purpose of the Study:
- To evaluate the theoretical and practical implications of combining antiviral agents for chronic hepatitis B.
- To assess the current evidence supporting combination therapies, including PEG-IFN plus NAs and different NAs.
- To review clinical guidelines regarding combination treatment strategies.
Main Methods:
- Review of existing studies on combination antiviral therapies for chronic hepatitis B.
- Analysis of virological advantages and limitations of combined treatments.
- Examination of clinical practice guidelines from major hepatology associations.
Main Results:
- Several studies indicate virological advantages for combination therapies.
- Pivotal prospective studies demonstrating long-term clinical benefits are currently lacking.
- Combination of PEG-IFN and NAs is not currently indicated by major guidelines.
Conclusions:
- While combination therapies show promise in virological markers, robust clinical evidence for long-term patient benefit is absent.
- Current guidelines do not support routine use of PEG-IFN plus NAs combination therapy.
- Guidelines permit limited use of nucleos(t)ide analogue combinations in specific clinical scenarios.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.8K
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
14.1K
Related Concept Videos
01:25Hepatitis
66
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
66
01:10Retrovirus Life Cycles
50.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.8K
01:30Inhibitors of Viral Protein Synthesis
47
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
47
01:28Viral Hepatitis I: Introduction
15
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
15
01:28Pulmonary Tuberculosis V
943
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
943
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
365
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
365